These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38619005)

  • 1. Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
    Jasmine S; Mandl A; Krueger TEG; Dalrymple SL; Antony L; Dias J; Celatka CA; Tapper AE; Kleppe M; Kanayama M; Jing Y; Speranzini V; Wang YZ; Luo J; Trock BJ; Denmeade SR; Carducci MA; Mattevi A; Rienhoff HY; Isaacs JT; Brennen WN
    Prostate; 2024 Jul; 84(10):909-921. PubMed ID: 38619005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer.
    Mandl A; Jasmine S; Krueger T; Kumar R; Coleman IM; Dalrymple SL; Antony L; Rosen DM; Jing Y; Hanratty B; Patel RA; Jin-Yih L; Dias J; Celatka CA; Tapper AE; Kleppe M; Kanayama M; Speranzini V; Wang YZ; Luo J; Corey E; Sena LA; Casero RA; Lotan T; Trock BJ; Kachhap SK; Denmeade SR; Carducci MA; Mattevi A; Haffner MC; Nelson PS; Rienhoff HY; Isaacs JT; Brennen WN
    bioRxiv; 2024 Jan; ():. PubMed ID: 38328141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.
    Etani T; Suzuki T; Naiki T; Naiki-Ito A; Ando R; Iida K; Kawai N; Tozawa K; Miyata N; Kohri K; Takahashi S
    Oncotarget; 2015 Feb; 6(5):2865-78. PubMed ID: 25605246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
    Hiatt JB; Sandborg H; Garrison SM; Arnold HU; Liao SY; Norton JP; Friesen TJ; Wu F; Sutherland KD; Rienhoff HY; Martins R; Houghton AM; Srivastava S; MacPherson D
    Clin Cancer Res; 2022 Oct; 28(20):4551-4564. PubMed ID: 35920742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
    Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysine-Specific Demethylase 1 (LSD1) Inhibitors: Peptides as an Emerging Class of Therapeutics.
    Baby S; Shinde SD; Kulkarni N; Sahu B
    ACS Chem Biol; 2023 Oct; 18(10):2144-2155. PubMed ID: 37812385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer.
    Turnham DJ; Mullen MS; Bullock NP; Gilroy KL; Richards AE; Patel R; Quintela M; Meniel VS; Seaton G; Kynaston H; Clarkson RWE; Phesse TJ; Nelson PS; Haffner MC; Staffurth JN; Pearson HB
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.
    Li M; Liu M; Han W; Wang Z; Han D; Patalano S; Macoska JA; Balk SP; He HH; Corey E; Gao S; Cai C
    Cancer Res; 2023 May; 83(10):1684-1698. PubMed ID: 36877164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice.
    Matsuda S; Baba R; Oki H; Morimoto S; Toyofuku M; Igaki S; Kamada Y; Iwasaki S; Matsumiya K; Hibino R; Kamada H; Hirakawa T; Iwatani M; Tsuchida K; Hara R; Ito M; Kimura H
    Neuropsychopharmacology; 2019 Jul; 44(8):1505-1512. PubMed ID: 30580376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
    Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
    J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
    Sehrawat A; Gao L; Wang Y; Bankhead A; McWeeney SK; King CJ; Schwartzman J; Urrutia J; Bisson WH; Coleman DJ; Joshi SK; Kim DH; Sampson DA; Weinmann S; Kallakury BVS; Berry DL; Haque R; Van Den Eeden SK; Sharma S; Bearss J; Beer TM; Thomas GV; Heiser LM; Alumkal JJ
    Proc Natl Acad Sci U S A; 2018 May; 115(18):E4179-E4188. PubMed ID: 29581250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
    Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R
    Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
    Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
    Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
    DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
    Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LSD1 Histone Demethylase Assays and Inhibition.
    Hayward D; Cole PA
    Methods Enzymol; 2016; 573():261-78. PubMed ID: 27372757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models.
    Yang CY; Lin CK; Tsao CH; Hsieh CC; Lin GJ; Ma KH; Shieh YS; Sytwu HK; Chen YW
    Oncotarget; 2017 May; 8(20):33756-33769. PubMed ID: 28422711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
    Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
    Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function.
    Kumaraswamy A; Duan Z; Flores D; Zhang C; Sehrawat A; Hu YM; Swaim OA; Rodansky E; Storck WK; Kuleape JA; Bedi K; Mannan R; Wang XM; Udager A; Ravikumar V; Bankhead A; Coleman I; Lee JK; Morrissey C; Nelson PS; Chinnaiyan AM; Rao A; Xia Z; Yates JA; Alumkal JJ
    JCI Insight; 2023 Aug; 8(15):. PubMed ID: 37440313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.